Ceyhun BOZKURT, Nazmiye YÜKSEK, Gürses ŞAHİN, Sonay İNCESOY ÖZDEMİR, Eda BALKAYA

Alteration in Characteristics and Outcome of Pediatric Burkitt Lymphoma in Turkey: Single-center Experience

OBJECTIVEBurkitt Lymphoma (BL) is an aggressive and rapidly progressive form of non-Hodgkin’s lymphomas(NHL), and BL gives rise to 3-4% of all childhood malignancies. Its event-free survival has increased upto 85% with current treatment protocols. In this study, we aimed to investigate whether there are somealterations of the clinical and laboratory features of BL at our center in Turkey before and now, or not.METHODSWe gathered medical records of a total of 101 patients with BL who were treated in our center retrospectively and assessed for laboratory findings, clinical characteristics, prognostic factors and treatmentprotocols.RESULTSWe found that, nowadays, intra-abdominal presentation of BL was seen more frequently than past at ourcenter in Turkey. However, there was no statistically significant difference. BL was numerically meaningful. Murphy’s treatment protocol was more satisfactory compared to past treatment protocols.CONCLUSIONOur comparison of the previous and present features of patients showed that there is a shift away from thejaw to mostly intra-abdominal disease presentation at our center, like Uganda, in the course of time. Andwe also have a large number of patients and the follow-up period is very long (median 111 months for allpatients) in the literature. We think that the intra-abdominal component is seen more in our geography withtime, but it should be evaluated with more studies in other geographies, especially in Europe and America.

PDF

___

1. Miles RR, Arnold S, Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/ leukaemia. Br J Haematol 2012;156(6):730−43.
2. Ferry JA. Burkitt’s Lymphoma: Clinicopathologic Features and Differential Diagnosis. Oncologist 2006;11(4):375−83.
3. Leoncini L, Raphael M, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt Lymphoma. In; Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Lyon, France: IARC Press, 2008.p. 262−4.
4. Hudson MM, Onciu M, and Donaldson SS. Hodgkin lymphoma. In: Pizzo PA, Poplack DG editors. Principles, and Practice of Pediatric Oncology, 7th ed. Philedelphia: Lipincott Williams & Wilkins, 2011. p. 722−36.
5. Lanzkowsky P. Manuel of Pediatric Hematology and Oncology, 4th edition. Elsevier, 2005.p. 491−511,777,786.
6. Robertson ES. Burkitt lymphoma. New York: Springer; 2013. p. 81−131.
7. Wright DH, Addis BJ, Leong ASY. Diagnostic Lymph Node Pathology, 2nd edition. CRC Press, 2011. p. 85−6.
8. Cairo MS, Sposto R, Perkins SL, Meadows AT, HooverRegan ML, Anderson JR, et al. Burkitt’s and Burkitt like lymphoma in children and adolescents: a review of the Children’s Cancer Group experience. Br J Haematol 2003;120(4):660−70.
9. Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM. Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer 2008;123(11):2658−63.
10.Al-Attar A, Pritchard J, Al-Saleem T, Al-Naimi M, Alash N, Attra A. Intensive chemotherapy for non-localised Burkitt’s lymphoma. Arch Dis Child 1986;61(10):1013−9.
11.Murphy SB, Bowman WP, Abromowitch M, Mirro J, Ochs J, Rivera G, et al. Results of treatment of advanced-stage Burkitt’s lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high- -dose methotrexate and cytarabine. J Clin Oncol 1986;4(12):1732−9.
12.Cunha KC, Oliveira MC, Gomes AC, de Castro LP, Viana MB. Clinical course and prognostic factors of children with Burkitt’s lymphoma in a developing country: the experience of a single centre in Brazil. Rev Bras Hematol Hemoter 2012;34(5):361−6.
13.Ertem U, Duru F, Pamir A, Taçyildiz N, Dağdemir A, Akçayöz A, et al. Burkitt’s Lymphoma in 63 Turkish Children Diagnosed Over a 10 Year Period. Pediatric Hematology and Oncology 1996;13(2):123−34.
14.Tınaztepe B, Göğüş S, Tınaztepe S. Burkitt lenfoma: Hacettepe Çocuk Hastanesinde görülen 32 vakanın patolojik incelenmesi ve Afrikalı çocuklardakilerle karşılaştırılması. Turkish J Pathology 1975;2(3):201−11.
15.Cavdar AO, Gözdaşoğlu S, Yavuz G, Babacan E, Unal E, Uluoğlu O, et al. Burkitt’s lymphoma between African and American types in Turkish children: clinical, viral (EBV), and molecular studies. Med Pediatr Oncol 1993;21(1):36−42.
16.Cavdar AO, Yavuz G, Babacan E, Gözdasoglu S, Unal E, Ertem U, et al. Burkitt’s lyphoma in Turkish children: clinical, viral (EBV) and molecular studies. Leukemia & Lymphoma 1994;14(3-4):323−30.
17.Karakaş Z, Bülbül A, Anak S, Ünüvar A, Sarıbeyoglu ET, Devecioglu Ö, et al. Burkitt’s lymphoma in childhood : ten years follow-up. Türk Onkoloji Derg 2004;19(1):3−8.
18.Celkan TT, Bariş S, Ozdemir N, Ozkan A, Apak H, Doğru O, et al. Treatment of pediatric Burkitt lymphoma in Turkey. J Pediatr Hematol Oncol 2010;32(7):e279−84.
19.Karadeniz C, Oguz A, Citak EC, Uluoglu O, Okur V, Demirci S, et al. Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center. Pediatr Hematol Oncol 2007;24(6):417−30.
20.Kutluk T, Varan A, Akyüz C, Büyükpamukçu M. Clinical characteristics and treatment results of LMB/LMT regimen in children with non-Hodgkin’s lymphoma. Cancer Invest 2002;20(5-6):626−33.
21.Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, Riehm H, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005;131(1):39−49.
22.Mbulaiteye SM, Biggar RJ, Bhatia K, Linet MS, Devesa SS. Sporadic childhood Burkitt lymphoma incidence in the United States during 1992-2005. Pediatr Blood Cancer 2009;53(3):366−70.
23.Mwanda OW, Rochford R, Moormann AM, Macneil A, Whalen C, Wilson ML. Burkitt’s lymphoma in Kenya: geographical, age, gender and ethnic distribution. East Afr Med J 2004;81(8):68−77.
24.Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E. Burkitt’s lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci 2007;7(3):166−75.
25.Owusu L, Yeboah FA, Osei-Akoto A, Rettig T, Arthur FK. Clinical and epidemiological characterisation of Burkitt’s lymphoma: an eight-year case study at Komfo Anokye Teaching Hospital, Ghana. Br J Biomed Sci 2010;67(1):9−14.
26.Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, et al. The Société Française d’Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97(11):3370−9.
27.Hassan R, Klumb CE, Felisbino FE, Guiretti DM, White LR, Stefanoff CG, et al. Clinical and demographic characteristics of Epstein-Barr virus-associated childhood Burkitt’s lymphoma in Southeastern Brazil: epidemiological insights from an intermediate risk region. Haematologica 2008;93(5):780−3.
28.Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol 2012;30(4):387−93.
29.Al-Attar A, Attra A, Al-Bagdadi R, Al-Naimi M, AlSaleem T, Pritchard J. Debulking’ surgery is unnecessary in advanced abdominal Burkitt lymphoma in Iraq. Br J Cancer 1989;59:610−2.
30.Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB. Treatment of children and young adults with early-stage non-hodgkin’s lymphoma. New England J Med 1997;337:1259−66.